Search Results - "Stegnar, M."

Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose by Herman, D, Locatelli, I, Grabnar, I, Peternel, P, Stegnar, M, Mrhar, A, Breskvar, K, Dolzan, V

“…Warfarin is an anticoagulant drug with narrow therapeutic index and high interindividual variability in dose requirement. S-warfarin is metabolized mainly by…”
Get full text

Nurr1 Haplotypes are Associated with Femoropopliteal Restenosis/Re-occlusion after Percutaneous Transluminal Angioplasty by Božič-Mijovski, M, Bedenčič, M, Stegnar, M, Salapura, V, Ježovnik, M.K, Kozak, M, Blinc, A

“…Abstract Restenosis/re-occlusion remains a frequent complication in the first year after percutaneous transluminal angioplasty (PTA). In this study,…”
Get full text

Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss by MAVRI, A, ALESSI, M. C, BASTELICA, D, GEEL-GEORGELIN, O, FINA, F, SENTOCNIK, J. T, STEGNAR, M, JUHAN-VAGUE, I

“…Abdominal fat produces plasminogen activator inhibitor-1 (PAI-1) and could contribute to increased plasma PAI-1 values in human obesity associated with insulin…”
Get full text

Prevention of ischemic events in patients with peripheral arterial disease design, baseline characteristics and 2-year results an observational study by Blinc, A, Kozak, M, Sabovic, M, Božic, M, Stegnar, M, Poredoš, P, Kravos, A, Barbic-Žagar, B, Pohar Perme, M, Stare, J

“…Peripheral arterial disease (PAD) is associated with frequent cardiovascular ischemic events. We followed the survival of PAD patients and tested whether PAD…”
Get more information

Do baseline serum leptin levels predict weight regain after dieting in obese women? by Mavri, A., Stegnar, M., Sabovic, M.

“…SUMMARY Aim  Weight loss achieved during weight reduction programme is difficult to maintain. We investigated the possible role of circulating leptin in…”
Get full text

Seasonal variation of some metabolic and haemostatic risk factors in subjects with and without coronary artery disease by Mavri, A, Gužič-Salobir, B, Salobir-Pajnič, B, Keber, I, Stare, J, Stegnar, M

“…Acute myocardial infarction (AMI) is more frequent in winter months than in summer months. The aetiologic mechanisms underlying this seasonal pattern are…”
Get full text

Novel non-covalent azaphenylalanine thrombin inhibitors with an aminomethyl or amino group at the P1 position by Obreza, A, Stegnar, M, Urleb, U

“…Design, synthesis and biological evaluation of a series of novel non-covalent azaphenylalanine thrombin inhibitors are presented. Replacement of the basic…”
Get more information

Design, synthesis and molecular modelling of 1-amidinopiperidine thrombin inhibitors by Smolnikar, I, Perdih, A, Stegnar, M, Prezelj, A, Solmajer, T, Urleb, U, Obreza, A

“…Design, synthesis and biochemical evaluation of a series of novel non-covalent thrombin inhibitors with a 1-amidinopiperidine moiety are presented. Replacement…”
Get more information

Classic risk factors, hypercoagulability and migraine in young women with cerebral lacunar infarctions by Salobir, B., Šabovič, M., Peternel, P., Stegnar, M., Grad, A.

“…Objective– Lacunar cerebral infarctions (LACI) in young women is a rare condition which pathogenesis is still not fully recognized. We explored the presence of…”
Get full text

Synthesis and in vitro evaluation of new azaphenylalanine derivatives as serine protease inhibitors by Obreza, A, Stegnar, M, Trampus-Bakija, A, Prezelj, A, Urleb, U

“…New inhibitors of serine proteases with azaphenylalanine scaffold were synthesized and their activity was evaluated in vitro. We studied the effect of…”
Get more information

Novel thrombin inhibitors with azaphenylalanine scaffold by Zega, A, Trampus-Bakija, A, Fortuna, M, Stegnar, M, Tschopp, T B, Steiner, B, Urleb, U

“…In this paper the synthesis and antithrombotic activity of a series of novel thrombin inhibitors with azaphenylalanine scaffold are described. By systematic…”
Get more information

Lysing patterns of retracted blood clots with diffusion or bulk flow transport of plasma with urokinase into clots--a magnetic resonance imaging study in vitro by Blinc, A, Keber, D, Lahajnar, G, Stegnar, M, Zidansek, A, Demsar, F

“…Fresh retracted clots are known to be poorly lysable by fibrinolytic agents. We have studied whether lysis of retracted clots could be enhanced by bulk…”
Get more information

Screening for selective thrombin inhibitors in mushrooms by Doljak, B, Stegnar, M, Urleb, U, Kreft, S, Umek, A, Ciglarič, M, Štrukelj, B, Popovič, T

“…Thrombin is the key serine proteinase of the coagulation cascade and therefore a suitable target for inhibition of blood coagulation. A number of…”
Get full text

Reproducibility of fibrinolytic response to venous occlusion in healthy subjects by Stegnar, M, Mavri, A

“…Fibrinolytic response to venous occlusion is used to assess the efficiency of the fibrinolytic system. Reproducibility of fibrinolytic variables after 20 min…”
Get more information

Alteration of the fibrinolytic system in patients with peripheral arterial occlusive disease by Poredos, P, Stegnar, M, Gacnik, A

“…The fibrinolytic system may play an important role in the development and progression of peripheral arterial occlusive disease. The fibrinolytic system of the…”
Get more information

Different tissue plasminogen activator release in the arm and leg during venous occlusion is equalized after DDAVP infusion by Keber, D, Stegnar, M, Kluft, C

“…The mechanism of tissue plasminogen activator (t-PA) release during arm and leg venous occlusions and DDAVP (1-desamino-8-D-arginine vasopressin) infusion was…”
Get more information

High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy by Vene, Nina, Mavri, Alenka, Kosmelj, Katarina, Stegnar, Mojca

“…Atrial fibrillation (AF) is associated with hemostatic abnormalities and increased risk of thrombotic cardiovascular events even during oral anticoagulant…”
Get more information

Tissue-type plasminogen activator after venous occlusion in pregnancy and puerperium by Stegnar, M, Zore, A, Novak-Antolic, Z, Vovk, N, Kruithof, E K

“…Pregnancy is associated with depressed fibrinolysis as judged from the decreased fibrinolytic response to venous occlusion. In order to elucidate if this…”
Get more information

Tissue plasminogen activator release in chronic venous hypertension due to heart failure by Keber, I, Keber, D, Stegnar, M, Vene, N

“…In order to study the effects of chronic venous hypertension due to heart failure on blood fibrinolytic activity, tissue plasminogen activator (t-PA) antigen,…”
Get more information

Toward a Novel Class of Antithrombotic Compounds with Dual Function. Discovery of 1,4-Benzoxazin-3(4H)-one Derivatives Possessing Thrombin Inhibitory and Fibrinogen Receptor Antagonistic Activities by Štefanič Anderluh, Petra, Anderluh, Marko, Ilaš, Janez, Mravljak, Janez, Sollner Dolenc, Marija, Stegnar, Mojca, Kikelj, Danijel

“…A novel class of potential antithrombotic compounds with moderate thrombin inhibitory and fibrinogen receptor antagonistic activity is described. Combination…”
Get full text